(Q42597029)

3 November 2017

Safety and effectiveness of olanzapine versus conventional antipsychotics in the acute treatment of first-episode schizophrenic inpatients (English)

1 reference

3 November 2017

0 references

1

Julio Bobes

1 reference

3 November 2017

Juan Gibert

2

1 reference

3 November 2017

Antonio Ciudad

3

1 reference

3 November 2017

Enrique Alvarez

4

1 reference

3 November 2017

Fernando Cañas

5

1 reference

3 November 2017

José-Luis Carrasco

6

1 reference

3 November 2017

Josep Gascón

7

1 reference

3 November 2017

Juan-Carlos Gómez

8

1 reference

3 November 2017

Miguel Gutiérrez

9

1 reference

3 November 2017

language of work or name

1 reference

1 May 2003

1 reference

Progress in Neuro-Psychopharmacology & Biological Psychiatry

3 November 2017

1 reference

3 November 2017

27

1 reference

3 November 2017

3

1 reference

3 November 2017

473-481

1 reference

Safety of olanzapine versus conventional antipsychotics in the treatment of patients with acute schizophrenia. A naturalistic study

3 November 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0278-5846%2803%2900035-6

7 January 2021

Olanzapine versus placebo: results of a double-blind, fixed-dose olanzapine trial

1 reference

https://api.crossref.org/works/10.1016%2FS0278-5846%2803%2900035-6

7 January 2021

Olanzapine versus haloperidol: acute phase results of the international double-blind olanzapine trial.

1 reference

https://api.crossref.org/works/10.1016%2FS0278-5846%2803%2900035-6

7 January 2021

Defining treatment refractoriness in schizophrenia

1 reference

https://api.crossref.org/works/10.1016%2FS0278-5846%2803%2900035-6

7 January 2021

Radioreceptor binding profile of the atypical antipsychotic olanzapine.

1 reference

https://api.crossref.org/works/10.1016%2FS0278-5846%2803%2900035-6

7 January 2021

One hundred years of schizophrenia: a meta-analysis of the outcome literature.

1 reference

https://api.crossref.org/works/10.1016%2FS0278-5846%2803%2900035-6

7 January 2021

THE NURSES' OBSERVATION SCALE FOR INPATIENT EVALUATION: A NEW SCALE FOR MEASURING IMPROVEMENT IN CHRONIC SCHIZOPHRENIA

1 reference

https://api.crossref.org/works/10.1016%2FS0278-5846%2803%2900035-6

7 January 2021

https://api.crossref.org/works/10.1016%2FS0278-5846%2803%2900035-6

1 reference

7 January 2021

The effects of atypical antipsychotic drugs on neurocognitive impairment in schizophrenia: a review and meta-analysis

1 reference

https://api.crossref.org/works/10.1016%2FS0278-5846%2803%2900035-6

7 January 2021

Fluphenazine dose, clinical response, and extrapyramidal symptoms during acute treatment

1 reference

https://api.crossref.org/works/10.1016%2FS0278-5846%2803%2900035-6

7 January 2021

The UKU side effect rating scale. A new comprehensive rating scale for psychotropic drugs and a cross-sectional study of side effects in neuroleptic-treated patients

1 reference

https://api.crossref.org/works/10.1016%2FS0278-5846%2803%2900035-6

7 January 2021

Duration of psychosis and outcome in first-episode schizophrenia

1 reference

https://api.crossref.org/works/10.1016%2FS0278-5846%2803%2900035-6

7 January 2021

A selective review of recent North American long-term followup studies of schizophrenia

1 reference

https://api.crossref.org/works/10.1016%2FS0278-5846%2803%2900035-6

7 January 2021

Olanzapine versus haloperidol treatment in first-episode psychosis

1 reference

https://api.crossref.org/works/10.1016%2FS0278-5846%2803%2900035-6

7 January 2021

Gender differences in onset of illness, treatment response, course, and biologic indexes in first-episode schizophrenic patients

1 reference

https://api.crossref.org/works/10.1016%2FS0278-5846%2803%2900035-6

7 January 2021

The McLean First-Episode Psychosis Project: six-month recovery and recurrence outcome

1 reference

https://api.crossref.org/works/10.1016%2FS0278-5846%2803%2900035-6

7 January 2021

Negative symptoms: a path analytic approach to a double-blind, placebo- and haloperidol-controlled clinical trial with olanzapine

1 reference

https://api.crossref.org/works/10.1016%2FS0278-5846%2803%2900035-6

7 January 2021

Blind, controlled, long-term study of the comparative incidence of treatment-emergent tardive dyskinesia with olanzapine or haloperidol

1 reference

https://api.crossref.org/works/10.1016%2FS0278-5846%2803%2900035-6

7 January 2021

Olanzapine versus haloperidol in the treatment of schizophrenia and schizoaffective and schizophreniform disorders: results of an international collaborative trial

1 reference

https://api.crossref.org/works/10.1016%2FS0278-5846%2803%2900035-6

7 January 2021

Extrapyramidal symptoms and tolerability of olanzapine versus haloperidol in the acute treatment of schizophrenia

1 reference

https://api.crossref.org/works/10.1016%2FS0278-5846%2803%2900035-6

7 January 2021

Early intervention for schizophrenia: can the course of the illness be altered?

1 reference

https://api.crossref.org/works/10.1016%2FS0278-5846%2803%2900035-6

7 January 2021

10.1016/S0278-5846(03)00035-6

Identifiers

DOI

1 reference

3 November 2017

1 reference